Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

v3.19.3
Net Loss Per Share
9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Net Loss Per Share

11. Net Loss Per Share


Basic net loss attributable to Heat Biologics, Inc per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.


For the three and nine months ended September 30, 2019 and 2018, all the Company’s common stock options, unvested restricted stock units and warrants were anti-dilutive and therefore have been excluded from the diluted calculation.


The following potentially dilutive securities were excluded from the calculation of diluted net loss per share in the three and nine months ended September 30 due to their anti-dilutive effect:


 

 

 

2019

 

2018

 

Outstanding stock options

 

 

 

3,163,354

 

 

465,406

 

Restricted stock subject to forfeiture and restricted stock units

 

 

 

838,429

 

 

61,144

 

Outstanding common stock warrants

 

 

 

9,030,730

 

 

4,430,730